Mitchell Revill

634 total citations
6 papers, 359 citations indexed

About

Mitchell Revill is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mitchell Revill has authored 6 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 2 papers in Oncology and 2 papers in Cancer Research. Recurrent topics in Mitchell Revill's work include RNA modifications and cancer (2 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Lung Cancer Research Studies (2 papers). Mitchell Revill is often cited by papers focused on RNA modifications and cancer (2 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Lung Cancer Research Studies (2 papers). Mitchell Revill collaborates with scholars based in United Kingdom, United States and Singapore. Mitchell Revill's co-authors include Paul D. Smith, Armelle Logié, Nicky Whalley, Susan E. Critchlow, Haihong Zhong, Clare Murray, Lorraine Mooney, Nicola J. Curtis, David C. Blakey and Brett P. Monia and has published in prestigious journals such as Nature Communications, Cancer Research and British Journal of Cancer.

In The Last Decade

Mitchell Revill

6 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitchell Revill United Kingdom	6	249	117	115	41	27	6	359
Hyo-Eun Moon South Korea	8	297 1.2×	93 0.8×	144 1.3×	32 0.8×	24 0.9×	9	420
Mesquita Rodrigues Portugal	6	251 1.0×	115 1.0×	194 1.7×	18 0.4×	31 1.1×	7	385
Ilenia Agliarulo Italy	11	372 1.5×	75 0.6×	159 1.4×	26 0.6×	48 1.8×	12	476
Chandrika Jeyamohan United States	6	224 0.9×	89 0.8×	145 1.3×	45 1.1×	35 1.3×	9	358
Sara Faouzi France	4	209 0.8×	82 0.7×	127 1.1×	24 0.6×	41 1.5×	11	341
Mingxue Geng Germany	5	216 0.9×	80 0.7×	68 0.6×	25 0.6×	28 1.0×	8	322
Janet N. Milliman United States	5	318 1.3×	114 1.0×	163 1.4×	48 1.2×	28 1.0×	5	467
Carmen E. Pyragius Australia	10	248 1.0×	84 0.7×	121 1.1×	18 0.4×	54 2.0×	10	393
Barbara Antoniani Italy	13	327 1.3×	143 1.2×	135 1.2×	47 1.1×	27 1.0×	20	463
Valérie Vial France	8	205 0.8×	68 0.6×	147 1.3×	16 0.4×	35 1.3×	14	332

Countries citing papers authored by Mitchell Revill

Since Specialization

Citations

This map shows the geographic impact of Mitchell Revill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Revill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Revill more than expected).

Fields of papers citing papers by Mitchell Revill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell Revill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Revill. The network helps show where Mitchell Revill may publish in the future.

Co-authorship network of co-authors of Mitchell Revill

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell Revill. A scholar is included among the top collaborators of Mitchell Revill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell Revill. Mitchell Revill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Revill, Mitchell, Alice Lallo, Melanie Galvin, et al.. (2021). Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. Nature Communications. 12(1). 6652–6652. 16 indexed citations

2.

Revill, Mitchell, Kristopher K. Frese, Melanie Galvin, et al.. (2020). The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. Journal of Thoracic Oncology. 15(12). 1836–1843. 48 indexed citations

3.

Ross, Sarah J., Alexey S. Revenko, Lyndsey Hanson, et al.. (2017). Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Science Translational Medicine. 9(394). 143 indexed citations

4.

Curtis, Nicola J., Lorraine Mooney, Filippos Michopoulos, et al.. (2017). Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity. Oncotarget. 8(41). 69219–69236. 121 indexed citations

5.

Beloueche‐Babari, Mounia, Yann Jamin, Simon Walker‐Samuel, et al.. (2013). Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. British Journal of Cancer. 109(6). 1562–1569. 20 indexed citations

6.

Critchlow, Susan E., Lorraine Mooney, Nicola J. Curtis, et al.. (2012). Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1). Cancer Research. 72(8_Supplement). 3224–3224. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact